|
May 29
|
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
|
|
May 29
|
ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials
|
|
May 28
|
ORIC Reports Preliminary Efficacy in Metastatic Prostate Cancer Study; Starts $125 Million Private Placement
|
|
May 28
|
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
|
|
May 28
|
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC
|
|
May 27
|
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
|
|
May 27
|
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC
|
|
Apr 16
|
Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds?
|
|
Feb 18
|
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
|
|
Jan 3
|
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|